Literature DB >> 10334143

Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group.

V Calvo1, J M Borro, P Morales, A Morcillo, R Vicente, V Tarrazona, F París.   

Abstract

INTRODUCTION: Fungal infections occur frequently in lung transplant patients, with the highest risk being in the early postoperative period (the initial hospitalization after lung transplantation). Aspergillus is responsible for more than half of all fungal infections, and Aspergillus has even been considered a contraindication for lung transplantation because of its difficult therapy and frequently fatal outcome. The aim of this article is to evaluate the success of an antifungal prophylaxis protocol to prevent fungal infection in the immediate postoperative period in lung transplant recipients.
MATERIAL AND METHODS: From March 1994 to March 1997, we performed 52 lung transplants in 31 men and 21 women who received antifungal prophylaxis with fluconazole, 400 mg/d, and aerosolized amphotericin B, 0.6 mg/kg/d, during the postoperative period.
RESULTS: The mean (+/- SD) postoperative period duration was 49 +/- 27.5 days. No fungal infections were observed during this period, and all patients provided negative cultures. We also found no toxicity related to antifungal drugs. The dose of cyclosporine was easily adjusted in every recipient according to blood levels so that effective immunosuppression was not compromised. DISCUSSION: In our study, the removal of the lungs and antifungal prophylaxis with fluconazole and aerosolized amphotericin B prevented fungal infection in the postoperative period in all 52 lung transplant recipients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10334143     DOI: 10.1378/chest.115.5.1301

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

Review 1.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

2.  Anti-Aspergillus Prophylaxis in Lung Transplantation: A Systematic Review and Meta-analysis.

Authors:  Archana Bhaskaran; Khalid Mumtaz; Shahid Husain
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

Review 3.  Perioperative antibiotics in thoracic surgery.

Authors:  Stephanie H Chang; Alexander S Krupnick
Journal:  Thorac Surg Clin       Date:  2011-10-20       Impact factor: 1.750

4.  Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?

Authors:  Rafael Zaragoza; Javier Pemán; Miguel Salavert; Angel Viudes; Amparo Solé; Isidro Jarque; Emilio Monte; Eva Romá; Emilia Cantón
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

Review 5.  Strategies for the Prevention of Invasive Fungal Infections after Lung Transplant.

Authors:  Roni Bitterman; Tina Marinelli; Shahid Husain
Journal:  J Fungi (Basel)       Date:  2021-02-07

Review 6.  Conventional Antifungals for Invasive Infections Delivered by Unconventional Methods; Aerosols, Irrigants, Directed Injections and Impregnated Cement.

Authors:  Richard H Drew; John R Perfect
Journal:  J Fungi (Basel)       Date:  2022-02-21

7.  Late respiratory infection after lung transplantation.

Authors:  Sang Young Kim; Jung Ar Shin; Eun Na Cho; Min Kwang Byun; Hyung Jung Kim; Chul Min Ahn; Suk Jin Haam; Doo Yun Lee; Hyo Chae Paik; Yoon Soo Chang
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-02-28

Review 8.  Immunosuppressive therapy in allograft transplantation: from novel insights and strategies to tolerance and challenges.

Authors:  Ammar Ebrahimi; Seyed Ahmad Hosseini; Fakher Rahim
Journal:  Cent Eur J Immunol       Date:  2014-10-14       Impact factor: 2.085

Review 9.  Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections.

Authors:  Kévin Brunet; Jean-Philippe Martellosio; Frédéric Tewes; Sandrine Marchand; Blandine Rammaert
Journal:  Pharmaceutics       Date:  2022-03-14       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.